Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study-Reference-Cited by-同舟云学术

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study

Published:2014-08 Issue:9 Volume:15 Page:1019-1026
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Younes Anas,Thieblemont Catherine,Morschhauser Franck,Flinn Ian,Friedberg Jonathan W,Amorim Sandy,Hivert Benedicte,Westin Jason,Vermeulen Jessica,Bandyopadhyay Nibedita,de Vries Ronald,Balasubramanian Sriram,Hellemans Peter,Smit Johan W,Fourneau Nele,Oki Yasuhiro

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. Cancer statistics, 2014;Siegel;CA Cancer J Clin,2014

2. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11;Ferlay,2013

3. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project;Blood,1997

4. Diffuse large cell lymphoma;Coiffier;Curr Opin Oncol,2001

5. Pathogenesis of human B cell lymphomas;Shaffer;Ann Rev Immunol,2012

Cited by 232 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Insights into First-Line Therapy in Diffuse Large B-Cell Lymphoma: Are We Improving Outcomes?;Journal of Clinical Medicine;2024-03-27

2. Efficacy and safety of Orelabrutinib-based regimens in diffuse large B-cell lymphoma: a single-center retrospective analysis;Clinical and Experimental Medicine;2023-11-04

3. Efficacy and safety of Orelabrutinib-based regimens in diffuse large B-cell lymphoma: A single-center retrospective analysis;2023-08-04

4. Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial;Blood Advances;2023-05-11

5. Chemotherapy;Medicines for Cancer;2023